Screener
Cytek Biosciences, Inc. CTKB Business Segments — Total stock-based compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Amortization - license & IP expense | 481 | 481 | 962 | 974 |
| Sales (excluding stock-based compensation) | 9,042 | 7,832 | 17,855 | 16,438 |
| Marketing (excluding stock-based compensation) | 3,357 | 3,066 | 5,411 | 5,765 |
| Research and development (excluding stock-based compensation) | 8,649 | 7,403 | 17,290 | 15,551 |
| General and administrative (excluding stock-based compensation) | 14,088 | 10,509 | 30,166 | 20,644 |
| Stock-based compensation expense | 5,339 | 6,791 | 10,200 | 13,421 |
| Other segment items | 758 | (5,041) | 1,160 | (8,614) |
| Net loss | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s business segments — total stock-based compensation?
- Cytek Biosciences, Inc. (CTKB) reported business segments — total stock-based compensation of $5.34M in Q2 2026.
- How has Cytek Biosciences, Inc.'s business segments — total stock-based compensation changed year-over-year?
- Cytek Biosciences, Inc.'s business segments — total stock-based compensation decreased by 21.4% year-over-year, from $6.79M to $5.34M.
- What is the long-term trend for Cytek Biosciences, Inc.'s business segments — total stock-based compensation?
- Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — total stock-based compensation has grown at a 14.0% compound annual growth rate (CAGR), from $16.59M to $24.59M.
- What does business segments — total stock-based compensation mean?
- Represents the total non-cash expense recognized for equity-based awards granted to employees and management within the segment. This metric is essential for understanding the dilution impact and the total cost of human capital.
Ask your AI about Cytek Biosciences, Inc.'s business segments — total stock-based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude